Teyi Pharmaceutical GroupLtd Past Earnings Performance
Past criteria checks 2/6
Teyi Pharmaceutical GroupLtd has been growing earnings at an average annual rate of 9.9%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 4.4% per year. Teyi Pharmaceutical GroupLtd's return on equity is 4.1%, and it has net margins of 9.1%.
Key information
9.9%
Earnings growth rate
5.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 4.4% |
| Return on equity | 4.1% |
| Net Margin | 9.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
We Think Teyi Pharmaceutical GroupLtd (SZSE:002728) Can Stay On Top Of Its Debt
Jun 06
Why Teyi Pharmaceutical GroupLtd's (SZSE:002728) Shaky Earnings Are Just The Beginning Of Its Problems
Apr 26Teyi Pharmaceutical Group Co.,Ltd's (SZSE:002728) Shares Bounce 29% But Its Business Still Trails The Market
Mar 06Here's Why We Think Teyi Pharmaceutical GroupLtd (SZSE:002728) Is Well Worth Watching
Feb 27Revenue & Expenses Breakdown
How Teyi Pharmaceutical GroupLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 778 | 71 | 217 | 44 |
| 30 Jun 24 | 843 | 104 | 234 | 45 |
| 31 Mar 24 | 928 | 157 | 244 | 44 |
| 31 Dec 23 | 1,067 | 253 | 241 | 43 |
| 30 Sep 23 | 1,049 | 269 | 225 | 43 |
| 30 Jun 23 | 1,040 | 269 | 213 | 40 |
| 31 Mar 23 | 996 | 238 | 196 | 40 |
| 31 Dec 22 | 887 | 178 | 177 | 38 |
| 30 Sep 22 | 816 | 122 | 175 | 39 |
| 30 Jun 22 | 785 | 113 | 169 | 38 |
| 31 Mar 22 | 758 | 131 | 161 | 38 |
| 01 Jan 22 | 758 | 127 | 178 | 38 |
| 30 Sep 21 | 725 | 118 | 159 | 37 |
| 30 Jun 21 | 691 | 92 | 158 | 38 |
| 31 Mar 21 | 652 | 63 | 159 | 37 |
| 31 Dec 20 | 633 | 44 | 153 | 36 |
| 30 Sep 20 | 668 | 66 | 200 | 38 |
| 30 Jun 20 | 743 | 108 | 223 | 39 |
| 31 Mar 20 | 852 | 155 | 246 | 42 |
| 31 Dec 19 | 921 | 172 | 267 | 44 |
| 30 Sep 19 | 939 | 168 | 292 | 42 |
| 30 Jun 19 | 949 | 171 | 274 | 49 |
| 31 Mar 19 | 926 | 171 | 264 | 48 |
| 31 Dec 18 | 885 | 156 | 258 | 47 |
| 30 Sep 18 | 828 | 146 | 208 | 56 |
| 30 Jun 18 | 777 | 128 | 177 | 66 |
| 31 Mar 18 | 739 | 112 | 161 | 56 |
| 31 Dec 17 | 687 | 106 | 149 | 46 |
| 30 Sep 17 | 689 | 110 | 160 | 27 |
| 30 Jun 17 | 680 | 105 | 190 | 0 |
| 31 Mar 17 | 650 | 94 | 193 | 0 |
| 31 Dec 16 | 656 | 95 | 187 | 0 |
| 30 Sep 16 | 648 | 85 | 184 | 0 |
| 30 Jun 16 | 631 | 84 | 176 | 0 |
| 31 Mar 16 | 584 | 80 | 161 | 0 |
| 31 Dec 15 | 517 | 81 | 139 | 0 |
| 30 Sep 15 | 419 | 78 | 94 | 0 |
| 30 Jun 15 | 356 | 74 | 77 | 0 |
| 31 Mar 15 | 355 | 78 | 68 | 0 |
| 31 Dec 14 | 345 | 80 | 66 | 0 |
| 30 Sep 14 | 347 | 82 | 62 | 0 |
| 30 Jun 14 | 345 | 85 | 83 | 0 |
| 31 Mar 14 | 337 | 82 | 69 | 0 |
| 31 Dec 13 | 343 | 81 | 56 | 0 |
Quality Earnings: 002728 has high quality earnings.
Growing Profit Margin: 002728's current net profit margins (9.1%) are lower than last year (25.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002728's earnings have grown by 9.9% per year over the past 5 years.
Accelerating Growth: 002728's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 002728 had negative earnings growth (-73.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).
Return on Equity
High ROE: 002728's Return on Equity (4.1%) is considered low.